Agreement is Largest Commitment to EVO ICL™ in the U.S.STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher end of $335-340 million outlook.
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance.
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.